Company news

PTC Therapeutics, Inc. news in 2025

PTC Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

December 21, 2025

PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

December 10, 2025

PTC Therapeutics to Host R&D Day

November 19, 2025

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 3, 2025

PTC Therapeutics to Participate at Upcoming Investor Conferences

October 30, 2025

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

October 20, 2025

PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

August 18, 2025

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025

Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin)

July 30, 2025

PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

July 27, 2025

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results

July 20, 2025

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

June 22, 2025

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 5, 2025

PTC518 PIVOT-HD Study Achieves Primary Endpoint

May 4, 2025

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

April 24, 2025

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

April 16, 2025

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

March 27, 2025

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

March 19, 2025

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

PTC Therapeutics to Participate in Upcoming Investor Conferences

February 19, 2025

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

February 18, 2025

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

February 12, 2025

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

January 12, 2025

Calls in 2025

Decks in 2025